OncoMatch/Clinical Trials/NCT07874308
HR20013 for the Prevention of Nausea and Vomiting in Patients With Cancer: A Real-World Study
Official title: A Real-World Study of the Efficacy and Safety of HR20013 for the Prevention of Antitumor Therapy-Induced Nausea and Vomiting in Patients With Cancer
Is NCT07874308 recruiting? Yes, currently enrolling (Oct 2026).
HR20013 is a newly approved medicine in China to prevent nausea and vomiting from anticancer treatment. This prospective, observational, multicenter real-world study will enroll about 3,000 patients receiving this medicine as routine care at over 30 hospitals in China, including 100 with mild to moderate hepatic impairment. Following usual clinical practice, it will evaluate how well the medicine prevents nausea and vomiting and its safety to guide clinical use.
Check if I qualifyExtracted eligibility criteria
Lab requirements
Liver function
Cohort 1: mild to moderate hepatic impairment (chronic liver injury from primary liver disease or liver metastases, plus at least one abnormal liver function indicator: ALT > ULN, AST > ULN, TBIL > ULN, DBIL > ULN, IBIL > ULN, ALP > ULN, GGT > ULN, ALB < ULN, TP < ULN, PT prolonged >3s, INR >1.7, ascites, or hepatic encephalopathy); Child-Pugh class A or B. Cohort 2: abnormal liver function indicators without primary liver disease (Child-Pugh not applicable). Severe hepatic impairment excluded from Cohort 2.
Cohort 1: chronic liver injury (primary liver disease, liver metastases, or documented liver injury) plus at least one abnormal liver function indicator (ALT > ULN, AST > ULN, TBIL > ULN, DBIL > ULN, IBIL > ULN, ALP > ULN, GGT > ULN, ALB < ULN, TP < ULN, PT prolonged >3s, INR >1.7, ascites, hepatic encephalopathy); Child-Pugh class A or B. Cohort 2: abnormal liver function indicators without primary liver disease (Child-Pugh not applicable). Severe hepatic impairment excluded from Cohort 2.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07874308 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify